Consistent with previous results, “identification” and “fibroblast growth factor 19” were major concerns in the initial stage; metabolic effects of FGF-21 were hot topics during the period 2008–2014, and the relationship between FGF-21 and metabolic disease, such as “atherosclerosis” and “fatty liver”, received attention later. Here, FGF21 is linked to metabolic disease.